(NAFLD) in rats and its potential underlying mechanisms. Treatment with 3Ac-OA (1-100 mol/L) dose-dependently decreased the intracellular levels of total cholesterol (TC) and triglyceride (TG) in FFA-treated primary rat hepatocytes and human HepG2 cell lines in vitro. Furthermore, oil red staining studies showed that 3Ac-OA caused dose-dependent decrease in the number of lipid droplets in FFA-treated primary rat hepatocytes. SD rats were fed a high fat diet (HFD) for 6 weeks and subsequently treated with 3Ac-OA (60, 30, 15 mg·kg -1 ·d -1 levels in HFD rats. Furthermore, 3Ac-OA administration ameliorated lipid accumulation and cell apoptosis in the liver of HFD rats. Using adipokine array analyses, we found that the levels of 11 adipokines (HGF, ICAM, IGF-1, IGFBP-3, IGFBP-5, IGFBP-6, lipocalin-2, MCP-1, M-CSF, Pref-1 and RAGE) were increased by more than twofold in the serum of 3Ac-OA-treated rats, whereas ICAM, IGF-1 of glucose transporter type 2 (GLUT-2) and low-density lipoprotein receptor (LDLR), as well as the phosphorylation of AMP-activated this study demonstrates that 3Ac-OA exerts a protective effect against hyperlipidemia in NAFLD rats through AMPK-related pathways.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is considered to be the most common chronic liver disease and affects millions of people worldwide [1] . NAFLD has emerged as an integral part of metabolic syndrome and is associated with obesity, hyperlipidemia and diabetes [2, 3] . NAFLD ranges from steatosis to the more aggressive non-alcoholic steatohepatitis (NASH) [4] . Several influencing factors, such as insulin resistance, lipid accumulation, inflammation and oxidative stress, have also been recognized as characteristic inducers of NAFLD [5, 6] . Characterized by large fat droplet accumulation, NAFLD induces dysregulation of fatty acid metabolism, and acid metabolism in the liver induces excessive lipid accumulation [7] . Significant overloading of FFA stimulates hepatic TG synthesis and directly causes hepatic lipotoxicity and [8] . Treatment strategies for NAFLD are mainly focused on dietary changes, enhancement of exercise levels and additional medication to ameliorate slight disease states.
is used to treat hyperlipidemia [2] . However, when confronted with serious disease conditions, we lack effective treatment strategies. Therefore, a comprehensive and directed treatment for targeting hepatic lipid regulation remains to be developed.
Oleanolic Acid (OA) is a commonly used natural compound and exerts beneficial effects against diabetes and metabolic syndrome [9, 10] . Our previous studies have shown that OA can against hypoglycemia in vivo [11] [12] [13] . 3-Acetyl-Oleanolic Acid (3Ac-OA) is synthesized based on OA. We hypothesized that 3Ac-OA might have a therapeutic effect on NAFLD and ameliorate hyperlipidemia. The present study investigated the 
Materials and methods
Chemicals and reagents 3Ac-OA ( Figure 1 ) was obtained from the Center for Drug of the drugs used in the present study were dissolved in a 0.5% carboxymethylcellulose sodium (CMC-Na) solution.
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and hemoglobin Alc kits were purchased from Whitman Biotech (Nanjing, China). Antibodies Isolation, culture and FFA treatment of primary rat hepatocytes (SD) rats (250-300 g) were cultured as previously described [14] .
the HepG2 cells. Cell imaging by oil red O staining was used to measure the lipid contents. The intracellular TG and TC levels were measured.
Animals and treatments
Male Sprague Dawley rats (180-200 g) were purchased from the Shanghai Laboratory Animal Center (Shanghai, China). Animals were allowed free access to food and water throughout acclimatization and experimental periods. To examine the protective effects of 3Ac-OA on HFD-induced hyperlipidemia, rats were randomly assigned to the following six groups (n=8): (I) vehicle group (0.5% CMC-Na, normal diet); (II) HFD group (0.5% CMC-Na, high fat diet); (III) HFD plus 6 weeks. The ingredients of the high fat diet included 2% cholesterol, 0.5% sodium cholate, 3% lard oil, 0.2% propylthiouracil and 94.3% basic fodder, which were mixed and irradiated with cobalt-60 (radiation dose 25.0 kGy) before use. The HFD was provided by the Jiangsu Xietong Biohandled according to university and institutional legislation,
Histopathology analysis
tissue regions (4 μm) were stained with hematoxylin and eosin -ined by a professional pathologist blinded to the treatment Oil Red O staining by cell imaging. Neutral lipid accumulation was determined -and mounted on slides, air-dried, and then fixed in ice-cold 10% formalin for 5-10 min. Slides were rinsed immediately in distilled water 3 times and then placed in absolute propylene for 8-10 min in a 60 ºC oven. Slides were then differentiated in an 85% propylene glycol solution for 2-5 min and rinsed twice in distilled water prior to staining in Mayer's hematoxylin for 30 s. After washing thoroughly in running tap water for 3 min, slides were placed in distilled water, mounted with glycerin jelly and observed by ImageJ software (National Institutes
Nile Red staining
The lipid level in primary rat hepatocytes was determined 3.7% formaldehyde for 10 min, and incubated for 3 min with --
Biochemical analysis
The serum lipid levels of TC, TG, LDL and HDL were investigated to evaluate the relative lipid content changes via commercially available kits provided by Whitman Biotech (Nanjing, China). The liver triglyceride and total cholesterol levels were analyzed according to the manufacturer's protocol. The liver index was calculated as follows and used to assess organ health and hepatic histological damage: Liver index=liver
Electron microscopy -aldehyde and treated as Wu described [15] . After rinsing in 0.1 1% OsO 4 for 1 h, dehydrated, and embedded with epoxy resin.
were taken under an electron microscope.
Rat adipokine array
Blood samples were clotted for 2 h at room temperature and then centrifuged for 20 min at 1000×g. Serum samples were repeated freeze-thaw cycles. The relative expression levels of 30 rat adipokines were determined simultaneously by using an adipokine array following the protocol provided in the kit. 3Ac-OA decreases food consumption, body weight, liver weight and serum biochemical parameters in HFD-treated rats To determine whether 3Ac-OA had anti-steatotic effects in vivo, rats were fed a vehicle (0.5% CMC-Na) and HFD containing 2% cholesterol once daily by intragastric administration for 6 weeks, followed by treatment with 3Ac-OA for 4 weeks. Compared with the control group, the HFD group showed a significantly lower average weight and food intake, but marked lipid accumulation and histological indications. In the process of raising the rats, we observed that rats fed a HFD had no appetite because of the food was full of oil. However, the HFD group. Treatment of rats with 3Ac-OA at 30 or body weight. There was no significant difference in the daily food intake between the 3Ac-OA-treated and control groups. The 3Ac-OA treatment markedly decreased the levels of serum TC, TG and LDL in a dose-dependent manner.
Western blotting
effect on the HDL level in a dose-dependent manner, it still produced a superior result than atorvastatin. Furthermore, the liver triglyceride and cholesterol levels were reduced after 3Ac-OA treatment. By contrast, treatment with atorvastatin in rats fed a HFD for 4 weeks resulted in no change in these parameters (Table 1) . In our previous studies, 
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water intake, body weight, and plasma TC and TG levels of parameters in normal rats. 
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Acta Pharmacologica Sinica 3Ac-OA ameliorates HFD-induced lipid accumulation and cell apoptosis in rats group had significant inflammation, infiltration of lymphocytes and macrophages, steatosis and lipid droplet accumulation compared with the control group ( Figure 5A , 5B). 3Ac- 
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and only a small amount of hepatocyte degeneration in rats, superior to that of the atorvastatin treatment group ( Figure  5C ). Oil red O staining also showed marked lipid accumulation in the HFD-fed group compared with the control group ( Figure 6A, 6B) . Treatment with 3Ac-OA resulted in few cytoplasmic alterations in hepatocytes, and the lipid droplet levels microscopy to analyze the cell apoptosis and lipid accumulation induced by HFD. Compared to the control group ( Figure  7A ), cells displayed disruption of nuclear integrity and lysosomal structures, chromatin margination and condensation in effects in maintaining cell integrity ( Figure 7C ). 3Ac-OA sigAc-OA alters the secretion of multiple adipokines in HFD-induced rats Adipokine array analyses showed that the secretion of multiple adipokines was altered by treatment with 3Ac-OA. The levels of eleven adipokines were increased by more than twofold in the serum of 3Ac-OA-treated rats, including HGF, Figure 6 . pokines, such as ICAM, IGF-1, and Lipocalin-2, had levels increased by more than twenty-fold. Most of the adipokines were associated with insulin-like growth factors.
3Ac-OA activates AMPK-related pathways
We also examined the effects of 3Ac-OA on energy metabolism signaling pathways. The HFD model group showed Discussion remains a major health problem throughout the world. Nonalcoholic fatty liver disease and its subtype non-alcoholic steatohepatitis affect approximately 35% of the population worldwide [16] . Half of all deaths in patients with non-alcoholic fatty liver disease are due to cardiovascular disease and malignancy, and yet overall disease awareness remains low. Despite new breakthroughs in hepatology, modern medicine lacks a reliable hepato-protective drug with few side effects [17] . Additionally, liver injury is one of the major side effects of many potential candidates, resulting in numerous failures of new drugs [18, 19] . It is well-known that an imbalance between TG excretion, synthesis and hepatic uptake of FFA will result in fatty liver disease. In hepatocytes, excess TG accumulation results [20] , whereas FFA and lipid metabolites potently cause lipoapoptosis and lipotoxicity. High concentrations of circulating FFA disrupt lipid metabolism in NAFLD patients, which may aggravate hepatic fat - [21] . FFA is the key player in the pathogenesis of NAFLD by influencing metabolic regulators [22] . In this study, FFA was used to induce lipid accumulation in primary rat hepatocytes and HepG2 cells, and 3Ac-OA reduced the levels of TC and TG at the cellular level. Furthermore, we established a NAFLD model by using HFD-fed rats. 3Ac-OA improved the metabolic and electron microscopy also showed similar results, and 3Ac-OA -ruption, the structural integrity of lysosomes, chromatin margination and condensation, and lipid accumulation in HFDinduced rats.
The present study demonstrated the protective effects of 3Ac-OA on FFA-induced lipotoxicity in vitro -mary rat hepatocytes and in vivo in HFD-induced hyperliphad a higher caloric intake and developed NAFLD to similar pathological degrees compared to rats in the control group. However, caloric intake in rats among the HFD fed groups biochemical index analysis showed a significant increases in the TG, TC, HDL-C and LDL-C levels of 49%, 195%, 46% and atorvastatin-treated group. Furthermore, similar pathological changes in NAFLD were induced in HFD-fed rats. The histopathological results showed that hepatocytes in the HFD-induced group underwent macrovascular cytoplasmic alterations. After treatment with 3Ac-OA, these changes were reversed in a dose-dependent manner, supporting that triterpenes have a positive hypolipidemic effect.
HFD-treated animals showed dyslipidemia and hepatic lipid accumulation; on the other hand, continuous HFD treatthe liver, which may develop to NASH. Similarly, the present investigation showed that rats with HFD-induced NAFLD exhibited higher levels of oxidative stress factors, lipid perstudy, we used a rat adipokine array kit to measure the relative expression levels of adipokines in serum. The results showed that 3Ac-OA increased secretion of HGF, ICAM-1, blood, was associated with cancer, diabetes and chronic kidney disease in a previous multiethnic study [23] . In this study, partly associated with lipid metabolism. Further details of the effects of the mechanism of 3Ac-OA on IGF pathways are under study .
redox homeostasis under various conditions [24] . A well--tant in the processes of glucose uptake and fatty acid oxidation; gluconeogenesis [25] [26] [27] . Due to its roles in energy regulation, the obesity and diabetes. The HFD model group showed a marked -naling pathways of hepatic insulin and obesity are impaired [28] . The 3Ac-OA exert its modulatory effects on NAFLD through multiple sigto address the detailed molecular mechanisms in vitro. Figure 8 . Secretion of various adipokines in serum from the control group, model group (HFD group), 3Ac-OA (30 mg/kg) group and 3Ac-OA (60 mg/kg) group were evaluated using a rat Antibody Array.
This project was partially aimed at drug discovery based on pharmacological interference with lipid metabolism. We previously focused on research and development of pentacyclic triterpenes as natural and low-toxic anti-diabetic agents, which are used to provide preventive and therapeutic effects against non-alcoholic fatty liver complications. The present study proin vivo in NAFLD models and in vitro hold great promise as a potential natural therapeutic agent for the treatment of NAFLD.
